The US Patent and Trademark Office has issued Pulmatrix two new patents, US Patent No. 8,992,983, “Respirably dry powder comprising calcium lactate, sodium chloride and leucine” and US Patent No. 9,061,352, “Dry powder formulations and methods for treating pulmonary diseases,” the company said. Pulmatrix now has 36 patents covering technology related to the iSPERSE (inhaled Small Particles Easily Respirable and Emitted) platform.
Pulmatrix announced a merger with Ruthigen in March 2015 and in June announced a development deal with Mylan.
Pulmatrix CEO Robert W. Clarke commented, “These issuances build upon previously issued international patents and reflect our aggressive strategy to broadly protect the global IP position of our core iSPERSE technology. Our issued and pending patents are the result of the research and development conducted in our labs and which formed the basis for our most advanced clinical-stage candidate, a branded generic bronchodilator for COPD, and our proprietary development candidate, an anti-fungal for cystic fibrosis. We look forward to the receipt of additional patents covering distinct as well as overlapping components and combinations of our iSPERSE technology and drug development candidates.”
Read the Pulmatrix press release.
